EMADINE
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMADINE is an ophthalmic solution approved in 1997 for eye-related indications. It is a small-molecule therapeutic delivered as eye drops. The specific mechanism of action and indication details are not publicly disclosed in available sources.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating team focus shifting toward lifecycle management and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EMADINE currently has zero linked job openings, reflecting its LOE stage and mature market position. Career opportunities are concentrated in commercial and lifecycle management roles focused on defending market share and transitioning to generic competition.
Brand ManagerProduct Manager
Worked on EMADINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.